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Herpes simplex virus type 2 (HSV-2) infections are associated with increased risk of HIV
transmission. We determined HSV-2 prevalence, incidence and associated risk factors, inci-
dence among persons with indeterminate results, and prevalence of HSV-2/HIV co-infection
among young adults (18–34 years) and adolescents (16–17 years) enrolled in an HIV inci-
dence cohort study in western Kenya.
Methods
Participants (n = 1106; 846 adults) were screened and those HIV-1 negative were enrolled
and followed-up quarterly for one year. HSV-2 was assessed using the Kalon enzyme
immunoassay. HSV-2 incidence was calculated separately among HSV-2 seronegative par-
ticipants and those indeterminate at baseline. Logistic regression was used to estimate the
odds of HSV-2 infection and Poisson regression was used to assess HSV-2 incidence and
associated factors.
Results
Overall, HSV-2 prevalence was 26.6% [95% confidence interval (CI): 23.9–29.4] and was
higher in adults (31.5% [95% CI: 28.3–34.9]) than adolescents (10.7% [95% CI: 7.1–15.3]).
Factors associated with prevalent HSV-2 included female gender, increasing age, HIV infec-
tion, history of sexually transmitted infection, low level of education, multiple sexual part-
ners, and being married, divorced, separated or widowed. Overall HSV-2 incidence was 4.0
per 100 person-years (/100PY) 95% CI: 2.7–6.1 and was higher in adults (4.5/100PY) and
females (5.1/100PY). In multivariable analysis only marital status was associated with HSV-
2 incidence. Among 45 participants with indeterminate HSV-2 results at baseline, 22 sero-
converted, resulting in an incidence rate of 53.2 /100PY [95% CI: 35.1–80.9]. Inclusion of
indeterminate results almost doubled the overall incidence rate to 7.8 /100 PY [95% CI: 5.9–
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10.5]. Prevalence of HIV/HSV-2 co-infection was higher in female adults than female ado-
lescents (17.1 [95% CI: 13.6–21.0] versus 3.4 [95% CI: 1.1–7.8]).
Conclusion
The high incidence rate among persons with indeterminate results underscores the public
health concerns for HSV-2 spread and underreporting of the HSV-2 burden. Careful consid-
eration is needed when interpreting HSV-2 serology results in these settings.
Introduction
Herpes simplex virus type 2 (HSV-2) infections are a leading cause of genital ulcer disease [1,
2]. Global burden of HSV-2 is about 11.3%, but prevalence varies in different regions, with
sub-Saharan Africa accounting for 31.5% of all infections worldwide [3]. Although HSV-2
infection generally has asymptomatic periods, it is capable of causing significant morbidity,
occurring mainly as ulcerative infections of the genital mucosa with painful lesions that may
be recurrent. Therefore, management of genital HSV-2 infection should address the chronic
nature of the disease rather than focusing solely on treatment of acute episodes of genital
lesions [4]. In addition, HSV-2 can be passed from mother to child during childbirth, causing
serious neonatal infections, which are usually fatal in the absence of treatment. Moreover,
HSV-2 infection has been linked to HIV infection, and it is believed to increase susceptibility
to HIV infection two to three fold and transmission of HIV infection by up to five fold. In fact,
nearly 50% of HIV infections in populations with at least 80% HSV-2 prevalence are attributed
to HSV-2 infections [5].
Because HSV-2 is chronic, periodically symptomatic, and capable of causing long-term
morbidity along with the risk of HIV acquisition [5], it is a significant public health concern,
which needs active prevention strategies, especially among the most at-risk populations [6].
Various studies have evaluated the risk factors for HSV-2 infection among high-risk groups
but few have been conducted in the general population, especially among adolescents. The
identification of risk factors is vital for prevention purposes, especially in areas at high risk of
HIV acquisition. Moreover, since HIV shares common risks with HSV-2, addressing the risk
factors of HSV-2 is likely to also reduce HIV infection rates. It is known that male circumci-
sion significantly reduces both HSV-2 and HIV infection [7]. This risk reduction is thought to
be mediated by a reduction in HSV-2-associated genital ulcers. Other identified risk factors for
HSV-2 include female gender[3], multiple sexual partners, young age of sexual debut, and pre-
vious history of sexual transmitted infections (STI) [4].
HSV-2 generally remains undiagnosed despite its high burden. This is because of its long
sub-clinical phase with varied and non-specific clinical manifestations. Most treatment gui-
delines are not specific or clear when referring to asymptomatic HSV-2 infections or inde-
terminate diagnosis. This lack of guideline specificity may limit appropriate preventive and
treatment efforts; hence, confirmatory laboratory testing is vital in HSV-2 diagnosis and
management. Commonly, HSV-2 testing is performed using serological enzyme-linked immu-
noassay (ELISA) tests. A challenge with these assays is the inconclusive diagnosis due to inde-
terminate results. Some studies have suggested raising the assay index value, especially in high
HSV-2 prevalence areas [8]. Most studies however, exclude the indeterminate results [9] since
there are no clear guidelines for management or therapy. This practice may create a biased
estimate of HSV-2 burden and also deny the opportunity for early or suppressive treatment
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and prevention efforts at the individual level. Our objectives were to determine HSV-2 preva-
lence, HSV-2 incidence, correlates of HSV-2 prevalence and incidence, HSV-2 incidence
among persons with indeterminate results, and prevalence of HSV-2 and HIV co-infection in
an HIV-1-at-risk and infected adult and adolescent population in western Kenya.
Materials and methods
Study population
Between January 2007 and June 2010, 1,106 adolescents (16–17 years) and young adults (18–
34 years) were screened for enrolment into the Kisumu Incidence Cohort Study (KICoS) from
the catchment area of Kisumu, in western Kenya [10]. The study procedures and methods for
screening, collection of demographics, behavioral and clinical information, HIV testing, and
quarterly follow-up have been previously described in detail [10]. Briefly, community engage-
ment occurred prior to initiating study recruitment in Kisumu and the surrounding area
(within 150 kilometres of the city). Convenience sampling was used to recruit study partici-
pants given that the parent study was designed to identify persons willing to participate in a
prospective study. At the baseline visit, we collected information on current and previous STIs,
sexual behavior, and socio-demographic characteristics, using staff-administered computer-
assisted personal interview (CAPI) and participant self-administered audio computer-assisted
self-interview (ACASI). In addition, participants underwent a medical examination and labo-
ratory testing for STIs, including HSV-2, regardless of symptoms. Rapid HIV testing was also
provided after counselling and those infected were referred for HIV care and treatment per the
national guidelines. Circumcision status was based on participant self-report. Laboratory
results were returned within two weeks and participants who tested positive for one or more
STI were treated and counselled.
Participants who reported having sexual intercourse at least once in the past three months
and were HIV-uninfected were enrolled and followed for a period of one year to determine
HIV incidence. Follow-up visits were conducted at the clinic every three months where data
were collected and blood drawn for HSV-2 and HIV testing. For those with symptoms, STIs
were tested and treated during the quarterly visits.
HSV-2 laboratory testing
Whole blood was collected from the study participants and taken to the ISO 15189 accredited
Kenya Medical Research Institute’s (KEMRI) HIV- Research laboratory collaborating with the
US Centers for Disease Control and Prevention (CDC), for serum separation and testing of
HSV-2. The HSV-2 IgG ELISA (Kalon Biological Limited, Guildford, UK) was performed on
all serum samples for the detection of IgG antibodies to HSV-2, with an adjusted cut-off of 2.0.
An outcome was considered positive if the optical density (OD) 2.0, negative if OD< cut-off
0.9 and indeterminate if cut-off 0.9sample OD < cut-off 2.0. Repeat testing was performed
on all positive or indeterminate samples along with 5% of randomly selected negative samples
per manufacturer’s recommendations as a quality assurance measure. HIV serostatus was
determined by a parallel testing algorithm of two enzyme immunoassays, at screening and pro-
spectively at each three-month interval visit, during the 12 months of follow-up.
Ethical review
This study was approved by the scientific steering and ethics review committees of KEMRI
(protocol no. SSC 1125), and the Institutional Review Board of the CDC (protocol no. 4938).
All participants provided signed informed consent with assent obtained in addition to
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parental/guardian consent for minors. All persons who took part in the eligibility screening
and follow-up visits received a standard transport reimbursement of KES 300 (USD 3.00). In
addition, participants received counselling and treatment for STIs and other common ailments
and were given condoms (men and women).
Statistical methods
Correlates of HSV-2 at baseline were assessed by use of sociodemographic and behavioral
covariates using logistic regression analysis. We assessed associations between HSV-2 inci-
dence with fixed covariates such as gender, age, marital status which were reported at enrol-
ment; time-varying covariates such as injections and drug use in the last three months which
were reported during follow-up visits. Variables with P< 0.25 were entered into a multivari-
able model to adjust for potential confounders.
The HSV-2 incidence rate was estimated using a generalized linear mixed model assuming
a Poisson distribution and using a log link function. This was performed using three methods:
1) on samples negative at baseline and positive at one year follow-up (confirmed HSV-2
infected), 2) on the indeterminate samples at baseline and HSV-2 positive at one year follow-
up, and 3) on the indeterminate samples at baseline and HSV-2 positive or indeterminate at
one year. Infection was assumed to have occurred at the mid-time point between the last visit
with negative and first visit with a positive serological test. Incidence was estimated per 100
person years (PY). Adjusted incidence rate ratios (adjIRRs) were estimated for fixed and time-
varying covariates (to account for changes in risk behaviours over time) using a Poisson
model. Exact binomial CIs were calculated for the prevalence estimates. Records with missing
data were dropped in the regression analysis.
Results
A total of 1,106 participants were screened, of whom 846 were adults and 260 were adolescents.
Of the 1,106 participants screened, 831 HIV-seronegative persons met the inclusion criteria
and were enrolled into the study; 625 adults (75.2%) and 206 (24.8%) adolescents. Twelve par-
ticipants, 8 adults and 4 adolescents, were HIV-infected during follow up, 5 of whom were
HSV-2 seropositive at baseline.
HSV-2 prevalence
Of 1,106 participants at screening, one participant had no HSV-2 result while 81 had indetermi-
nate HSV-2 results and were excluded from the analysis. Of 1,024 participants included in the
analysis, 492 (48.0%) were males and 243 (23.7) were adolescents. Overall, HSV-2 prevalence
was 26.6% (95% confidence interval [CI] 23.9% - 29.4) and was higher in adults than adoles-
cents; 31.5% (95% CI [28.3–34.9] and 10.7% CI [7.1–15.3] respectively (Table 1). Females gener-
ally had a higher HSV-2 prevalence than males, with a prevalence ratio of 3.4 (95% CI [2.6–4.4];
p<0.001) among adults and 9.0 (95% CI 2.1–37.1; p = 0.002) among adolescents (Table 1).
Correlates of HSV-2 prevalence
HSV-2 prevalence increased with age; those aged 18–24, 25–29 and 30–34 years had preva-
lence of 26.7%, 40.0% and 62.5% respectively. Prevalence was also higher in females (40.2%)
compared to male (11.8%), HIV-infected (75.2%) compared to HIV-uninfected (20.3%), mar-
ried (48.5%) or separated/divorced/widowed (62.2%) compared to single/never married
(15.7%), circumcised males (13.7%) compared to uncircumcised males (10.9%), and those
with previous STI (42.2%) compared to those never treated for an STI (24.0%) (Table 2).
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In the multivariable model, the odds of having a prevalent HSV-2 infection were higher
among adult participants compared to adolescents (16–17 years), with odds increasing with
Table 1. Prevalence of HSV-2 at enrolment, by gender and age-group, Kisumu Incidence Cohort Study, Kisumu, Kenya, 2007–2010.
Population HSV-2 Prevalence
N (%) 95% CI PR [95% CI]
p-value
Overall 272 (26.6) 23.9–29.4
Adults 246 (31.5) 28.3–34.9 <0.001
Adolescents 26 (10.7) 7.1–15.3 <0.001
Adulta Males 56 (14.4) 11.1–18.3 ref.
Adulta Females 190 (48.4) 43.3–53.4 3.4 [2.6–4.4] < 0.001
Adolescentb Males 2 (1.9) 0.2–6.8 ref.
Adolescentb Females 24 (17.3) 11.4–24.6 9.0 [2.1–37.1] 0.002














Overall prevalence 272 (24.6)
Age 16–17 years 26 (10.7) Ref <0.001 Ref <0.001
18–24 years 159 (26.7) 3.0 (2.0–4.8) <0.001 2.8 (1.6–5.0) <0.001
25–29 years 52 (40.0) 5.6 (3.3–9.5) <0.001 3.6 (1.8–7.5) <0.001
30–34 years 35 (62.5) 14.0 (7.1–27.4) <0.001 7.9 (3.0–21.0) <0.001
Gender Male 58 (11.8) Ref Ref
Female 214 (40.2) 5.0 (3.6–7.0) <0.001 7.3 (4.7–11.5) <0.001
HIV Status Uninfected 184 (20.3) Ref Ref
Infected 88 (75.2) 11.9 (7.6–18.7) <0.001 5.6 (3.2–9.8) <0.001
Education Technical training/College 39 (14.3) Ref Ref
Secondary 101 (28.7) 2.4 (1.6–3.6) <0.001 2.6 (1.6–4.2) <0.001
Primary 114 (32.4) 2.9 (1.9–4.3) <0.001 2.8 (1.6–4.8) <0.001
Never attended school 16 (39.0) 3.8 (1.9–7.8) 0.001 2.9 (1.1–7.6) 0.027
Marital Status Single/Never married 110 (15.7) Ref Ref
Married/living as married 131 (48.5) 5.1 (3.7–6.9) <0.001 2.5 (1.6–3.9) <0.001
Separated/Divorced/Widowed 28 (62.2) 8.9 (4.7–16.7) <0.001 3.4 (1.4–8.2) 0.008
Circumcision Status# Circumcised 26 (13.7) Ref
Uncircumcised 32 (10.9) 0.8 (0.4–1.3) 0.348
Ever treated for STI No 213 (24.0) Ref Ref
Yes 54 (42.2) 2.3 (1.6–3.4) <0.001 2.5 (1.5–4.2) 0.001
Lifetime number of sexual partners 0–1 partner 40 (22.5) Ref Ref
2–3 partners 104 (30.0) 1.5 (1.0–2.3) 0.069 2.0 (1.2–3.4) 0.014
 4 partners 118 (26.4) 1.2 (0.8–1.9) 0.309 2.1 (1.2–3.7) 0.008
#Applicable to male participants only
Abbreviations: HSV: Herpes Simplex Virus, CI: Confidence Interval, STI: Sexually transmitted infection, OR: Odds ratio
Definitions: Adults 18–34 years; Adolescents 16–17 years
https://doi.org/10.1371/journal.pone.0178907.t002
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age. The adjusted ORs (aOR) were 2.8 (95% CI 1.6–5.0), 3.6 (95% CI 1.8–7.5), and 7.9 (95% CI
3.0–21.0) for participants in the 18–24, 25–29, and 30–34 age groups, respectively. The odds of
having a prevalent HSV-2 infection were significantly associated with being female (aOR; 7.3,
95% CI 4.7–11.5), HIV-infected (aOR 5.6 95% CI 3.2–9.8), having a lack of formal education
(aOR 2.9, 95% CI 1.1–7.6) compared to those with college education, and married/cohabiting
(aOR 2.5, 95% CI 1.6–3.9) or separated/widowed/divorced (aOR 3.4, 95% CI 1.4–8.2) com-
pared to being single/never married. Additionally, HSV-2 prevalence was associated with a
history of treated STIs (aOR 2.5, 95% CI 1.5–4.2) and having four or more sexual partners
(aOR 2.1, 95% CI 1.2–3.7) (Table 2). HSV-2 prevalence increased with age for both men and
women, but the rate was always higher in the women (Fig 1).
HSV-2 incidence
Of 831 HIV-1-negative participants enrolled into the study, 157 were HSV-2 positive, 57 had
indeterminate results. One participant had missing results and was excluded from the inci-
dence analysis, leaving a total of 616 participants. The overall incidence of HSV-2 was esti-
mated at 4.0 (95% CI: 2.7–6.0) /100 PY (Table 3) for participants testing negative at enrolment
and followed through the twelve months of study. The incidence was higher in adults than
adolescents [(4.5, 95% CI: 2.8–7.1 versus 3.0 95% CI: 1.2–7.1)/100 PY, respectively] and
females had higher HSV-2 incidence than males (5.1, 95% CI: 2.8–9.3 versus 3.4, 95% CI: 1.9–
6.0)/100 PY, respectively (Table 3).
Correlates of HSV-2 incidence
The only factor associated with HSV-2 incidence in the multivariable analysis was being mar-
ried or cohabiting (risk ratio (RR) 2.8, 95% CI 1.5–5.5) (Table 4).
Fig 1. HSV-2 prevalence at enrolment, stratified by age group and gender, among participants in the Kisumu Incidence
Cohort Study, Kisumu, Kenya 2007–2010.
https://doi.org/10.1371/journal.pone.0178907.g001
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Table 3. HSV-2 incidence rates among HSV-2-negative participants at baseline compared to participants with HSV-2-negative/indeterminate
results at baseline during follow up, by age-group and gender, Kisumu Incidence Cohort Study, Kisumu, Kenya, 2007–2010.
HSV-2 incidence among HSV-2 negative
participants at baseline
HSV-2 incidence among participants with HSV-2 negative/Indeterminate
results at baseline
N Incidence/100PY 95% CI N Incidence/100PY 95% CI RR
[95%CI]
Cohort
Adults 440 4.5 2.8–7.1 484 9.0 6.6–12.4 2.8(1.2–8.0)
Adolescents 176 3.0 1.2–7.1 189 3.3 1.5–7.3 ref
Gender
Male 370 3.4 1.9–6.0 402 9.8 6.5–14.7 1.7(0.9–3.2)
Female 246 5.1 2.8–9.3 271 5.8 2.8–9.3 ref
Overall 616 4.0 2.7–6.0 673 7.3 5,5–9.8 7.3(5.5–9.8)
Abbreviations: HSV: Herpes Simplex Virus, CI: Confidence Interval, STI: Sexually transmitted infection, RR: Risk ratio, PY: Person years
Definitions: Adults 18–34 years; Adolescents 16–17 years
https://doi.org/10.1371/journal.pone.0178907.t003






Age group 16–17 years ref. ref.
18–24 years 2.4 (1.0–5.8) 0.047 2.1 (0.9–5.2)
25–29 years 3.2 (1.1–9.5) 0.032 2.3 (0.7–7.0)
30–34 years 3.2 (0.6–6.3) 0.156 1.8 (0.3–10.1) 0.306
Education Never attended school 3.4 (0.7–16.5) 0.132
Primary 2.0 (0.9–4.7) 0.090
Secondary 1.6 (0.7–3.9) 0.255
Technical training/College ref.
Marital Status Single/Never married ref. ref.
Married/living as married 1.84 (0.3–2.8) 0.545 2.8 (1.5–5.5) 0.040
Separated/Divorced/Widowed 1.9 (0.3–3.7) 0.542 1.8 (0.3–12.8)
Gender Male ref. ref.
Female 1.8 (1.0–3.3) 0.044 1.7 (0.9–3.2) 0.125
Had Forced sex in the last 3 months Yes ref.
No 1.0 (0.3–3.3) 0.966
Ever had anal sex Yes ref.
No 0.7 (0.3–1.6) 0.415
Had an injection in the last 3 months Yes 1.7 (0.9–1.1) 0.124 1.7 (0.9–3.3) 0.179
No Ref. ref.
Ever had a scarification Yes ref.
No 1.4 (0.5–4.6) 0.540
Ever had contact with someone else’s blood Yes ref.
No 0.8 (0.3–2.5) 0.705
Ever treated for STI Yes 1.5 (0.4–6.4) 0.552
No ref.
Ever had genital ulcers Yes 13.0 (1.9–87.3) 0.008 11.9 (1.8–79.2) 0.353
No ref. ref.
Abbreviations: HSV: Herpes Simplex Virus, CI: Confidence Interval, STI: Sexually transmitted infection, RR: Risk ratio
Definitions: Adults 18–34 years; Adolescents 16–17 years
https://doi.org/10.1371/journal.pone.0178907.t004
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HSV-2 incidence among persons with indeterminate results
Based on the inclusion criteria, 24 persons with indeterminate results at baseline were
excluded from the incidence analysis leaving a total of 57 participants. Of 57 participants with
indeterminate HSV-2 results at enrolment, 22 tested positive by the end of the 12-month fol-
low-up period; while, 23 remained indeterminate, 11 tested negative, and 1 had a missing
result. In calculating the incidence only among participants with indeterminate results, the 11
participants with HSV-2 negative results were excluded. Among the 45 persons with an inde-
terminate result, incidence was high; 53.2 (95% CI 35.1–80.9)/100 PY (Table 5).
When all participants with indeterminate results (N = 57) at screening were included in the
incidence analysis, the overall incidence increased to 7.3 [95% CI 5.5–9.8] (Table 3) from 4.0
[95% CI 2.7–6.0] /100PY. Incidence varied by age-group and gender; adults (vs adolescents)
had a risk ratio of 2.8 (95% CI 1.2–8.0) P = 0.0116, and males (vs females), 1.7 (95% CI 0.9–
3.2) P = 0.0851 (Table 3).
Prevalence of HSV-2 and HIV Co-infection
Prevalence of HIV/HSV-2 co-infection at enrolment was higher in female adults and adoles-
cents, 17.1 [CI 13.6–21.0] and 3.4 [CI 1.1–7.8] respectively compared to adult and adolescent
males, 2.9 [CI 1.5–5.0] and 0 [CI 0–3.2] respectively (Table 6). Five of 157 participants (3.2%)
Table 5. Estimated HSV-2 seroconversion rates by gender and age for HSV-2-indeterminate status participants who seroconverted during 12
months of follow-up. Kisumu Incidence Cohort Study, Kisumu, Kenya, 2007–2010.
HSV-2 positive
(N)
Incidence per 100PY 95% CI
Gender
Male 12 67.0 38.1–118.0
Female 10 42.7 23.0–79.4
Cohort
Adults 21 72.7 47.7–111.6
Adolescents 1 8.0 1.1–57.0
Total 22 53.2 35.1–80.9
Abbreviations: HSV: Herpes Simplex Virus, CI: Confidence Interval
Definitions: Adults 18–34 years; Adolescents 16–17 years
https://doi.org/10.1371/journal.pone.0178907.t005
Table 6. Estimated HSV-2/ HIV prevalence rates at enrolment by age-group and gender. Kisumu Incidence Cohort Study, Kisumu, Kenya, 2007–2010






Adult Male 12 2.9 [1.5–5.0] ref.
Adult Female 71 17.1 [13.6–21.0] 6.9 [3.6–14.2]
Adolescent Male 0 0 [0–3.2] ref.
Adolescent Female 5 3.4 [1.1–7.8] {undefined}
Adults 10.0 [8.0–12.2]
Adolescents 1.9 [0.6–4.5]
Abbreviations: HSV: Herpes Simplex Virus, CI: Confidence Interval, OR: Odds ratio
Definitions: Adults 18–34 years; Adolescents 16–17 years
https://doi.org/10.1371/journal.pone.0178907.t006
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who were HSV-2 seropositive and 7 participants (1.0%) of who were HSV-2 seronegative or
indeterminate at baseline acquired HIV infection during follow up.
Discussion
Overall, HSV-2 prevalence for this cohort was 26.6% and incidence was 4.0 /100PY. HSV-2 prev-
alence was higher among women when compared to men in all age groups in the study. Age-spe-
cific prevalence for women in this study was at least one and a half times as high as the national
prevalence. (40.2% vs 26.1% respectively) [11] In contrast, the prevalence in males was much
lower than the national prevalence (11.8% vs 26.1%). In our analysis, the observed low prevalence
for males compared to females, especially among the adolescents, is similar to what has been
reported for other STIs, including HIV, and may reflect age-mixing sexual practices in the region
[12]. Prevalence rates were lower for both adults and adolescents in all age groups in the current
study when compared to a 2009 study among a rural population within the same region. [12, 13].
In our study, HSV-2 prevalance was associated with several factors. The increasing preva-
lence with age, female gender, low level of education, number of lifetime sexual partners, HIV
co-infection, history of sexually transmitted infections, and currently or previously married
have also been reported by other studies in this region as HSV-2 associated factors [6, 10, 14].
The high HIV/HSV-2 co-infection observed in this study corroborates existing evidence of
synergistic relationship between the two diseases. A proposed mechanism for the synergy
includes a high risk of HIV acquisition in persons with HSV-2 due to an influx of HIV target
cells in response to HSV-2 replication in the genital mucosa. Conversely, the low immunity
associated with HIV infection is thought to increase suspectibility to HSV-2 infection. There-
fore, either of the viral infections augments infectivity of the other [14]. Moreover, persons
with both infections are equally at risk of transmitting either of the viruses. This suggests that
preventive efforts for either viral infection are likely to lead to a reduction in the other infec-
tion. Indeed HIV infection in this region follows a similar epidemiological pattern as that of
HSV-2 with infections in women increasing as age increases [12, 14].HIV surveys in Kenya
have reported a high prevalence of HSV-2 among currently and previously married persons
[14]. This association continues to suggest shared risk factors among the two viral infections
[15]. However, this could also indicate an increased risk of HIV acquisition from an HSV-2
infected partner or transmission by an HIV/HSV-2 coinfected index case due to repeated con-
tact among discordant couples. While previous clinical trials have failed to show a reduction in
risk of HIV acquisition in HSV-2 partners treated with acyclovir suppresive therapy [16, 17],
some trials have shown reduction in risk of transmission of HIV by the index case [16]. The
low transmission risk is mediated by a reduction in HIV RNA by 0.26–0.53 log10, as has been
reported in several clinical trials [16]. While the exact biological mechanism of HSV-2 and
HIV synergy is not completely understood, in vitro studies have shown the activation of HIV-1
target cells by genital herpes for HIV-1, as well as binding and transactivation of the long ter-
minal repeat region of HIV-1, subsequently increases HIV replication. Therefore, HSV-2 con-
trol and prevention could play a vital role in HIV-1 reduction in married couples specifally
among HIV or HSV-2 discordant couples.The association of HSV-2 with a history of STIs
may reflect a behavioral risk rather than biological. As has been reported in other studies,
there was an association between number of lifetime sexual partners and HSV-2 infection[14].
The association reflects the need for enhanced behavioural prevention efforts including risk-
reduction counselling for those engaging in multiple sexual partnerships.
In this study, the observed HSV-2 incidence was lower than what has been reported in
other studies in the region, especially among females. The male HSV-2 incidence was closer to
other areas such as Rakai in Uganda, which reported an incidence of 4.9 per 100py [18].
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A key finding in this analysis was the greater than half of participants with HSV-2 indeter-
minate results at baseline seroconverting, resulting in an incidence almost twice that of partici-
pants who were HSV-2-negative at baseline. Exclusion of indeterminate HSV-2 results in
incidence analysis calculations could have biased the observed incidence. Indeterminate infec-
tion is thought to be a result of increased cross-reactivity of HSV-2 antibodies with those of
other pathogens, or a reduced sensitivity of the Kalon HSV-2 IgG assay in detecting infections
during the seroconversion window. Our findings thus suggest the need for algorithms with a
higher index value for the screening tests to increase the sensitivity, especially among the inde-
terminate results [12, 19]. Alternatively, indeterminate sera need further analysis using a west-
ern blot assay to determine if the indeterminate have evidence of other HSV-2 specific bands
that appear earlier than IgG2. This is informed by uncertain on whether participants in the
indeterminate cohort are really HSV-2 seropositive and/or just starting to seroconvert because
IgG2 is a relatively late antibody acquisition and hence the follow-up sera may be a reactivation
rather than incident disease.
There were several limitation to our study. A key limitation is the low number of new HSV-
2 and exclusion of HIV-1 infections during the 12-month study period. This restricted the
ability to conclusively assess risk factors associated with new HSV-2 infections. Also, we used
convenience sampling method in our recruitment, which is likely to have introduced selection
bias. Additionally, because of the few responses to the circumcision question in our study, we
were unable to fully determine its true effect in prevention of HSV-2 infection, as shown in
other studies [7, 20]. Moreover, circumcision status was self-reported, hence we were unable
to verify the true status of participants who provided a response. Two covariates; forced sex
and anal sex had the most missing records in analysis of HSV-2 incidence with up to 280 rec-
ords missing from a total of 2300 records. This may have been related to the secrecy of sexual
encounters among this population. Finally, because we did not know if indeterminate results
were negative or positive at baseline, we could not ascertain whether the incidence was too
high or too low. However, despite these limitations, our results shed light on the need to re-
evaluate HSV-2 algorithms to improve sensitivity in detecting potential seroconverters.
In conclusion, our study highlights the need for prevention efforts of HSV-2 infections,
especially among adolescent girls, women, and married couples. With women being dispro-
portionately affected, there is an urgent need for HSV-2 control and prevention efforts target-
ing adolescent girls and women in this population. The high rate of seroconversion of persons
testing indeterminate at baseline, and the resulting increased HSV-2 incidence, underscores
the potential public health concerns for HSV-2 spread, as well as the underreporting of HSV-2
burden. Management of genital HSV-2 infections should take into consideration if/when to
treat persons with indeterminate results, who are generally asymptomatic, rather than focusing
solely on treatment of those symptomatic with genital lesions. There is a need to re-consider
the cut-off for interpretation of HSV-2 results by the Kalon serological assay to increase sensi-
tivity and specificity for identification of persons acutely infected with HSV-2.
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